-
Insulin degludec (INN/USAN) is an ultralong-acting
basal insulin analogue that was
developed by Novo
Nordisk under the
brand name Tresiba. It is administered...
-
Insulin degludec/liraglutide, sold
under the
brand name Xultophy, is a fixed-dose
combination medication for the
treatment of
adults with type 2 diabetes...
-
Insulin degludec/insulin aspart, sold
under the
brand name Ryzodeg, is a fixed-dose
combination medication for the
treatment of
diabetes mellitus. It contains...
- A10AE06
Insulin degludec A10AE07
Insulin icodec A10AE30
Combinations A10AE54
Insulin glargine and
lixisenatide A10AE56
Insulin degludec and liraglutide...
-
comparing insulin glargine to NPH insulin,
insulin detemir or
insulin degludec in the
management of type I
Diabetes in
neither adults or
children in periods...
- INN"
analogue approved in the USA- 2013 Novo Nordisk's
Tresiba "insulin
degludec INN"
analogue approved in
Europe (EMA with
additional monitoring] Walton...
- diabetes. Its
glycemic control and
safety were
found similar to
insulin degludec in a
phase II trial. Heise, Tim; Chien, Jenny; Beals, John M.; Benson,...
- NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide) inhalable...
-
tirzepatide was
observed to be
superior to dulaglutide, semaglutide,
degludec, and
insulin glargine with
regards to
glycemic efficacy and
obesity reduction...
-
Insulin glargine (Lantus)
Insulin detemir (Levemir)
Insulin degludec (Tresiba)
Insulin degludec is
sometimes classed separately as an "ultra-long" acting...
